Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data from a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial

TNM Classification of Malignant Tumors

1998 • 5,989 citations

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1991 • 3,493 citations

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

A p16 ^INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

1995 • 1,147 citations

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

1994 • 1,108 citations

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

1994 • 921 citations

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

1994 • 771 citations

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.

1994 • 522 citations

International Union Against Cancer (UICC)

2012 • 472 citations

Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

1992 • 410 citations

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

1995 • 324 citations

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1990 • 300 citations

Human Malignant Melanoma.

1980 • 287 citations

Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

1994 • 247 citations

Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

1988 • 239 citations

Active-specific immunotherapy for melanoma.

1990 • 186 citations

A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate

1983 • 171 citations

Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.

1989 • 130 citations

Cutaneous Melanoma

1986 • 122 citations

A phase III randomized, doúble-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma

1995 • 121 citations

Adjuvant therapy of cancer VI

1991 • 105 citations

Active Specific Immunotherapy of Melanoma with Allogeneic Cell Lysates Rationale, Results, and Possible Mechanisms of Actiona

1993 • 97 citations

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1992 • 89 citations

Spontaneous regression of malignant melanoma

1974 • 79 citations

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

1991 • 76 citations

A southeastern cancer study group phase I/II trial with vaccinia melanoma oncolysates

1986 • 65 citations

Biological therapy of cancer

1986 • 65 citations

Regression of primary melanoma with metastases

1992 • 64 citations

Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells

1985 • 61 citations

Positive Relationship of Clinical and Serologic Responses to Vaccinia Melanoma Oncolysate

1987 • 55 citations

Immunotherapy of Malignant Melanoma With Vaccinia Virus

1974 • 51 citations

Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma

1992 • 47 citations

Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.

1994 • 47 citations

Increased Survival of Patients Treated With a Vaccinia Melanoma Oncolysate Vaccine

1997 • 47 citations

Active specific immunotherapy in malignant melanoma

1989 • 41 citations

Approaches to Augmenting the IgG Antibody Response to Melanoma Ganglioside Vaccines

1993 • 35 citations

Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon α in a murine hepatic metastasis model

1990 • 30 citations

Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma

1993 • 29 citations

A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment.

1983 • 28 citations

Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.

1985 • 26 citations

Clinical Activity of a Polyvalent Melanoma Antigen Vaccine

1995 • 23 citations

Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model

1994 • 21 citations

Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial

1996 • 17 citations

Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2

1988 • 9 citations

Immunotherapy of a Vaccinia Colon Oncolysate Prepared with Interleukin-2 Gene-Encoded Vaccinia Virus and Interferon-α Increases the Survival of Mice Bearing Syngeneic Colon Adenocarcinoma

1994 • 7 citations

Eat your cereal

1996 • 4 citations

Deleted Work

1955 • 0 citations